Spruce

Spruce Biosciences is a clinical-stage biotechnology company developing novel therapies for rare endocrine disorders. Their lead product candidate, Tildacerfont, has the potential to be the first FDA-approved therapy for congenital adrenal hyperplasia (CAH), a rare endocrine disease where patients are unable to make normal levels of steroid in their body. The company is currently conducting Ph 2 clinical trials. Spruce went public in October 2020, listing on Nasdaq with the ticker: SPRB.